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In addition to its role in the pathophysiology of numerous psychiatric disorders, increasing
evidence points to serotonin (5-HT) as a crucial molecule for the modulation of
neurodevelopmental processes. Recent evidence indicates that the placenta is involved
in the synthesis of 5-HT from maternally derived tryptophan (TRP). This gives rise to
the possibility that genetic and environmental perturbations directly affecting placental
TRP metabolism may lead to abnormal brain circuit wiring in the developing embryo, and
therefore contribute to the developmental origin of psychiatric disorders. In this review, we
discuss how perturbations of the placental TRP metabolic pathway may lead to abnormal
brain development and function throughout life. Of particular interest is prenatal exposure
to maternal depression and antidepressants, both known to alter fetal development. We
review existing evidence on how antidepressants can alter placental physiology in its key
function of maintaining fetal homeostasis and have long-term effects on fetal forebrain
development.
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INTRODUCTION
There is a wealth of evidence suggesting that serotonin (5-HT)
plays a critical role in many neurodevelopmental processes. Basic
and epidemiological studies link disruption of the 5-HT pathway
to a host of developmental and functional disorders, yet direct
evidence of the molecular mechanisms underlying these pertur-
bations remains lacking, especially in humans. Studies in animal
models have indicated that 5-HT is a key modulator of neuronal
cell proliferation, migration, and brain wiring during fetal and
early postnatal development (Brezun and Daszuta, 1999, 2000,
2008; Azmitia, 2001; Kindt et al., 2002; Banasr et al., 2004; Bonnin
et al., 2007). Furthermore, genetic and environmental disruption
of 5-HT receptor function during critical periods of fetal brain
development inmice lead to behavioral abnormalities throughout
life, such as adult anxiety disorders (Gaspar et al., 2003; Holmes
et al., 2003a,b; Ansorge et al., 2004; Nordquist and Oreland, 2010;
Morelli et al., 2011; Garbett et al., 2012; Malkova et al., 2012).
Interestingly however, there is sparse evidence of specific associ-
ations between 5-HT receptor gene mutation or dysfunction and
mental illness in humans (Gingrich and Hen, 2001; Gaspar et al.,
2003; Segman et al., 2003).
Generally weak phenotypes in single receptor knockout mice
and the existence of 15 different receptor subtypes for 5-HT
suggest that genetic alteration of one specific subtype may be
compensated for by the presence of other pharmacologically and
functionally similar receptors (e.g., 5-HT1B and 5-HT1D recep-
tors; see Van Kleef et al., 2012). Basic studies were able to alter
function of several receptors simultaneously during restricted,
critical time periods, thus potentially preventing compensatory
signaling through other receptors and leading to clear phenotypes
(Ansorge et al., 2004; Bonnin et al., 2007).
What is common to all receptor subtypes is their endogenous
ligand, 5-HT. Therefore, altered 5-HT tissue concentration may
lead to generalized disruption of signaling through more than
one receptor type simultaneously. This possibility is supported
by dramatic effects from the pharmacological disruption of 5-HT
synthesis in early experiments, contrasting with mild effects of
single receptor knockout models (Van Kleef et al., 2012).
Recent results show that 5-HT signaling, and thus extracel-
lular levels of 5-HT, play a crucial role in the thalamocortical
wiring of the fetal forebrain by affecting netrin-1 mediated axonal
guidance (Bonnin et al., 2007, 2011). Thus, altered 5-HT con-
centration in the fetal brain tissue, in addition to signal/receptor
interaction, may have far-reaching developmental and functional
consequences (Bonnin and Levitt, 2012). A recent study showed
that the fetal forebrain accumulates placentally derived sero-
tonin during early pregnancy (Bonnin et al., 2011), a period
during which axons are experiencing active outgrowth and guid-
ance. The role of placental metabolism of 5-HT from maternally
derived TRP, its potential genetic and environmental perturba-
tions, and their downstream consequences are currently under
intense investigation.
5-HT AND FETAL BRAIN DEVELOPMENT
Serotonergic neurons are one of the most ubiquitous circuits in
the mammalian brain, forming early during fetal development,
and innervating essentially the entire central nervous system. The
early presence of 5-HT, as well as the proposed maternal ori-
gin of 5-HT, has led to the hypothesis that 5-HT may be an
essential growth and regulatory factor for the fetal brain dur-
ing critical periods of development (Lauder and Krebs, 1976;
Lidov and Molliver, 1982; Gaspar et al., 2003; Bayard et al., 2007;
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Bonnin et al., 2011; Migliarini et al., 2012). This is supported
by the idea that disruption of the 5-HT signaling system is a
key developmental component for a number of neuropsychiatric
disorders, such as schizophrenia, affective disorders, anxiety, and
autism (Chugani et al., 1999; Whitaker-Azmitia, 2001; Sodhi and
Sanders-Bush, 2004; Bonnin and Levitt, 2012). Genetic mouse
models have shown that excess levels of 5-HT in the brain,
obtained by knocking out the transporter (SERT; Slc6a4) or
monoamine oxidase-A (MAO-A) genes, which are involved in the
re-uptake and degradation of 5-HT, respectively, lead to abnormal
development of topographically organized whisker-barrel fields
in the somatosensory cortex (Cases et al., 1996; Persico et al.,
2001). Furthermore, recent studies have shown that increased
activity of the serotonergic pathway may lead to abnormal cor-
tical development and neuronal migration (Janusonis et al., 2004;
Riccio et al., 2009). On the other hand, 5-HT depletion through
the use of Pet1 knockout mice, in which there is a dramatic reduc-
tion of serotonergic neuron number and differentiation, shows no
identifiable gross brain malformations, despite evidence of later
behavioral and functional deficits (Hendricks et al., 2003; Liu
et al., 2010). Similarly, targeted inactivation of tryptophan hydrox-
ylase 2 (Tph2), the rate-limiting enzyme for the synthesis of 5-HT
specifically in the brain, in the mouse model has been demon-
strated to produce behavioral and functional deficits. However,
lack of 5-HT did not lead to obvious cellular or histological
abnormalities in the brain (Savelieva et al., 2008; Alenina et al.,
2009; Yadav et al., 2009). Nevertheless, the more recent analysis
of a knock-in mouse line, in which the brain-specific Tph2 gene
was replaced by an eGFP reporter, showed significant abnormal-
ities in serotonergic innervation in several regions of the rostral
brain (Migliarini et al., 2012). Combined, these data suggest that
specific circuits are finely tuned to 5-HT during their initial for-
mation, including the serotonergic system itself. The next logical
question is to determine if, and how, 5-HT signaling during devel-
opment is impacted by genetic and environmental perturbations
shown to be associated with increased risk of neuropsychiatric
disorders.
Recent work suggests that the maternal and placental source
of 5-HT may be a critical link between early genetic and
environmental perturbations and their impact on fetal brain
development. Consequently, exposure to pharmacological or
environmental insults, combined with genetic factors that disrupt
maternal or placentally derived 5-HT may have profound and
long-lasting consequences on the developing brain, leading to a
host of neuropsychiatric disorders thought to have developmental
origins.
In the next section, we discuss how particular environmental
and pharmacological insults such as exposure to maternal depres-
sion and antidepressants during pregnancymay impact fetal brain
development, taking into account the potential effects on the
maternal-fetal interface function.
PRENATAL EXPOSURE TO MATERNAL DEPRESSION AND
ANTIDEPRESSANTS, EFFECTS ON FETAL BRAIN
DEVELOPMENT AND LONG-TERM CONSEQUENCES
Major Depression Disorder (MDD) is a devastating mood dis-
order that indiscriminately affects individuals of all backgrounds
and ages, and is common even in women during gestation. In
fact, the prevalence of MDD is about 15% during pregnancy, and
Selective Serotonin Reuptake Inhibitors (SSRIs) are the primary
pharmacologic intervention (Oberlander et al., 2006). Despite an
unclear safety profile and a lack of well-controlled safety stud-
ies, an estimated 13% of pregnant women are prescribed an SSRI
antidepressant during all or part of their pregnancy (Cooper et al.,
2007). This common off-label use is warranted for its benefi-
cial effects of improving maternal mood and relieving symptoms
of depression, which presumably lead to better pregnancy out-
comes. Due to their high use and unknown safety, there is high
surveillance of SSRIs by the US Food and Drug Administration,
which has placed some SSRIs in Pregnancy Category D, indicating
demonstrated risks to the fetus (Greene, 2007).
Recent epidemiological studies suggest that fetal exposure
to maternal SSRI therapy is implicated in disturbing several
physiological and cognitive domains during fetal development.
Their prescribed use is associated with increased prevalence
of preterm delivery, intrauterine growth restriction, and neu-
robehavioral disturbances in infants (Oberlander et al., 2009).
Additionally, fetal SSRI exposure has been shown to increase risks
of Postnatal Adaptation Syndrome, low Apgar scores, Persistent
Pulmonary Hypertension of the Newborn, long-term changes in
cardiac morphology and physiology, gastrointestinal abnormali-
ties, Autism Spectrum Disorders, and postnatal language learn-
ing deficits in humans (Figure 1). (Cohen et al., 2000; Simon,
2002; Laine et al., 2003; Källén, 2004; Chambers et al., 2006;
Levinson-Castiel et al., 2006; Oberlander et al., 2006; Cooper
et al., 2007; Louik et al., 2007; Talge et al., 2007; Calderon-
Margalit et al., 2009; Lund et al., 2009; Merlob et al., 2009;
Pedersen et al., 2009, 2010; Hadjikhani, 2010; Kornum et al.,
2010; Reis and Källén, 2010; Croen et al., 2011; Haskell et al.,
2012; Jimenez-Solem et al., 2012; Nijenhuis et al., 2012a,b;
Nordeng et al., 2012; Weikum et al., 2012; Yonkers et al.,
2012).
Leaving maternal MDD untreated to avoid the potential ter-
atogenicity of SSRIs also poses significant risks. The anguish and
psychological distress accompanied by untreated MDD induces
considerable maternal stress, one of the earliest adverse experi-
ences with long-term effects on the offspring. Several animal and
human studies show that maternal stress or depression disrupt
fetal neurobehavioral development and affect cognitive, emo-
tional and behavioral outcomes throughout childhood (Peters,
1990; Hayashi et al., 1998; Talge et al., 2007; Homberg et al.,
2010). Children exposed to the stress induced by depressed moth-
ers are also at increased risk of developmental delay, impaired
language development, and even low IQ scores (Figure 1) (Deave
et al., 2008; Paulson et al., 2009). The impact of maternal depres-
sion on newborns has effects that last beyond infancy, as one-
third of school-aged children of depressed mothers suffer from
depression and anxiety disorders (Pilowsky et al., 2006). Beyond
childhood, animal studies have shown that neonatal SSRI expo-
sure suppresses adult serotonergic signaling and elicits depressive-
and anxiety-like behaviors in adulthood (Ansorge et al., 2008;
Shanahan et al., 2009).
Maternal depressive states and prenatal exposure to SSRIs
both alter fetal health. For the developing fetus, associated risks
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FIGURE 1 | (A) Treatment of maternal depression with SSRIs is
associated with varying pregnancy outcomes. While every gestational
stage of SSRI exposure has been implicated in increased risks for
cognitive, physiological, or developmental teratogenicity, the period of
exposure is an important factor that appears to influence clinical
outcomes in the offspring. We limited this list to outcomes that have
been the focus of several epidemiological studies in recent years and for
which differential exposure data during pregnancy was available.
(B) Untreated maternal depression and stress have been associated with
several risks that affect cognitive and developmental outcomes. While
associations are not generally correlated to specific trimesters, exposure
to untreated maternal depression or stress during pregnancy pose
adverse risks to fetal health and development. Study Selection and Data
Extraction Studies were selected if they had clearly identified maternal
SSRI exposure for specific trimesters of pregnancy and assessed
neonatal outcomes. Epidemiological studies that included medium-to-large
number samples exposed to different SSRI drugs were selected. Direct
comparison of absolute odds ratio values across these studies is not
possible due to varying specific study designs, adjustments for level of
maternal depression and various sociodemographic and lifestyle factors,
drug dosages, length of exposure, and SSRI treatment options. *PPHN,
Persistent pulmonary hypertension of the newborn.
stem from both the untreated illness and the treatment itself,
underscoring a therapeutic risk-benefit dilemma: SSRI treatments
that safeguard maternal health have adverse effects on the devel-
oping fetus, but leaving maternal depression untreated also poses
various significant, adverse risks.
Several perspectives have been offered to account for how some
psychiatric disorders may arise from the disruption of partic-
ular neurotransmitter systems during development. Disruption
during sensitive developmental periods may have lasting effects
expressed during adulthood, and since 5-HT signaling partici-
pates in several developmental programs (see above), dysfunction
of the 5-HT system may be implicated in the etiology of several
mental disorders in humans, particularly in MDD. Genetic stud-
ies in mice show that transient developmental disruption the
5-HT system by exposure to SSRIs results in long-term behavioral
abnormalities and increased anxiety in adult offspring (Ansorge
et al., 2004, 2008; Maciag et al., 2006; Oberlander et al., 2008).
Not only does neonatal SSRI exposure reduce serotonergic sig-
naling, but also elicits a down regulation in midbrain expression
of Tph2, an essential enzyme in the serotonin synthesis pathway
(see above, Maciag et al., 2006).
As mentioned above, studies in animal models point to evi-
dence that 5-HT influences mammalian nervous system devel-
opment. Disruption of 5-HT signaling has several important
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implications, namely in themodulation of axonal guidancemech-
anisms that establish precise fetal brain circuits (Gross et al., 2002;
Bonnin et al., 2006, 2007). Because embryonic thalamocortical
axons (TCAs) accumulate 5-HT and express a range of 5-HT
receptors as well as SERT, serotonin is able to shape the out-
growth and synaptic connectivity of their projections (Bonnin
et al., 2012). SSRIs target and block SERT with high affinity, and
have been shown to directly affect serotonergic modulation of
TCA responses to the guidance cue netrin-1 in vitro. The pres-
ence of the SSRI citalopram (R/S enantiomers mixture) switched
TCA response to netrin-1 from attraction to repulsion, impacting
the direction of their projections (Bonnin et al., 2012). Moreover,
mice with genetically disrupted SERT function, which may serve
as a model for chronic SSRI exposure, display changes in neuronal
cytoarchitecture, 5-HT function and neurobehaviors, all compo-
nents that have developmental origins (Oberlander et al., 2009).
In addition, genetic studies in mice show that disruption of 5-
HT receptors expression during a restricted period of pre- and
postnatal development results in long-term behavioral abnormal-
ities (Gross et al., 2002). Taken together, these results suggest that
SSRIs could induce topographical shifts in important circuits of
the fetal brain, thus constituting a possible mechanism that gives
rise to certain mental illnesses by altering circuit-formation and
ultimately, proper brain function later in life.
IMPACT OF SSRIs ON FETAL DEVELOPMENT MAY DEPEND
ON ROUTES OF EXPOSURE DURING PREGNANCY
The placenta is essential for ensuring the growth and survival
of the fetus during development. Not only does it support fetal
homeostatic functions, but also serves as the essential source of
5-HT for the fetal forebrain during a transient, critical period of
development (Bonnin et al., 2011; Bonnin and Levitt, 2012). The
placenta is able to synthesize 5-HT from a maternal TRP precur-
sor in both mice and humans (Bonnin et al., 2011; Bonnin and
Levitt, 2012; Goeden and Bonnin, 2013). This exogenous source
of 5-HT is available to the fetal brain during developmental mile-
stones including cortical neurogenesis, cell migration, and circuit
formation (Bonnin et al., 2011). Therefore, proper placental func-
tion during gestation may be essential for the 5-HT modulation
of neurodevelopment.
The placenta may play a major role between SSRIs expo-
sure and their associated teratogenicity during gestation. Since
the fetal brain acquires placenta-derived 5-HT during a critical
period of widespread axonal outgrowth, the effects of SSRIs on
fetal brain development may be through an indirect pathway that
affects proper placental physiology, resulting in indirect, down-
stream effects on the fetus. Although it is not clear whether SSRI
exposure induces physiological changes in the placenta, its high
expression of SERT support the notion that SSRIs would retain
their high binding affinity in this organ (Ganapathy et al., 1993;
Yavarone et al., 1993; Shearman et al., 1998; Verhaagh et al.,
2001). If blocking SERT function alters placental 5-HT synthe-
sis and/or transport to the fetus, or maternal 5-HT degradation,
SSRI treatments could be teratogenic primarily by altering pla-
cental physiology. The placenta’s key function of maintaining
fetal homeostasis may thus be compromised and have long-term
effects on fetal forebrain development.
Alternatively, SSRIs may be able to readily cross the placenta
and enter the fetal circulation, where they could directly target
the developing brain’s serotonergic system. While there is some
evidence of SSRIs crossing the placenta, studies have focused on
umbilical cord concentrations at birth in humans (Hostetter et al.,
2000; Hendrick, 2003; Sit et al., 2011). Several commonly used
SSRIs such as Citalopram, Fluoxetine, and Paroxetine were shown
to cross the placental barrier at term, with various efficiencies
(e.g., mean ratios of umbilical cord to maternal serum concentra-
tions ranged from 0.29 to 0.89) (Hendrick, 2003). These studies
give a snapshot of maternal-fetal SSRI transplacental transport at
birth; however, there is no data earlier in gestation, particularly
when the fetal brain may be most susceptible to disruptions of
5-HT signaling. Such data is difficult to obtain in humans, render-
ing studies in animal models as crucial and necessary to providing
key insights.
The impact of SSRIs on fetal brain development may there-
fore result from direct actions on the fetal brain, indirect actions
on placental or maternal physiology or, more likely, a combi-
nation of all these routes (Figure 2). Ongoing efforts to mea-
sure transplacental transfer and effects on placental physiology
of SSRIs throughout the course of pregnancy in mice, and
to determine the drugs biodistribution in the fetus, will help
determining precisely how they affect fetal brain development.
FIGURE 2 | The effects of SSRIs on fetal brain development may be
through direct (A) or indirect pathways that affect placental (B),
maternal (C), or both maternal and placental physiology (D), ultimately
resulting in downstream effects on the fetus. Direct effects (A) suggest
that SSRIs readily cross the placenta and enter the fetal circulation, where
they would directly target the developing brain’s serotonergic system.
Alternatively, physiological changes in the placenta (B), or delivery of
maternal factors essential for the developing fetal brain (C) may be affected
through indirect pathways. The combination of both direct and indirect
pathways inducing adverse effects on the fetal brain may also be possible
(D). Under the influence of varying s maternal, fetal and placental
(maternal-fetal combination) genetic susceptibilities (DNA double helix), the
effects of SSRI exposure at different pregnancy stages may lead to diverse
developmental outcomes.
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A CONCLUDING PERSPECTIVE ON THE ROLE OF 5-HT ON
THE NEURODEVELOPMENTAL PROGRAMMING OF MENTAL
DISEASES
Transient disruption of essential signaling events during crit-
ical developmental periods may have lasting effects that are
expressed throughout life. The serotonergic system steers neu-
rodevelopment through the key modulation of neurogenesis,
cell migration, and brain wiring that give rise to proper brain
function. With a diversity of molecular targets on which to
focus, it makes sense that perturbations of 5-HT signaling
have been implicated in the pathogenesis of diverse neurode-
velopmental disorders. The perturbations of the 5-HT neuro-
transmitter system during development, whether directly on
the fetal brain or on its placental modulation during early
gestation, may have long-lasting developmental and physio-
logical consequences. Risk factors, both genetic and environ-
mental, that alter 5-HT concentration in the fetal brain tissue
may thus ultimately pose far-reaching functional consequences
throughout life.
Fetal exposures to SSRIs and maternal stress induced by MDD
are early exposures that have been associated with various diseases
affecting physiological and cognitive domains. The heterogene-
ity and diversity of different disease outcomes is informed by the
length and developmental period of adverse exposures, in addi-
tion to fetal genetic susceptibilities. Together with the altered fetal
brain 5-HT signaling caused by SSRI exposure in different stages,
the influence of maternal, fetal and placental (maternal-fetal; see
Figure 2) genetics could possibly lead to different disease states.
The manifestation of several mental disorders associated with
serotonin dysfunction, namely MDD, ASD, and other psychi-
atric illnesses may thus require multiple events of environmental,
genetic, and their interactions, to occur.
While the associated risks from fetal SSRI exposure continue to
be elucidated, the mechanisms of 5-HT neurodevelopmental dis-
ruptions, and how they ultimately lead to adult-onset disorders
need further study. There is also a clinical demand for effective
and safe treatment of maternal MDD, taking into consideration
the effects of drug therapy on the safety of the developing fetus.
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